[1] LAKS S,MEYERS M O,KIM H J.Surveillance for gastric cancer[J].Surg Clin North Am,2017,97(2):317-331.
[2] KATONA B W,RUSTGI A K.Gastric cancer genomics:advances and future dIrections[J].Cell Mol Gastroenterol Hepatol,2017,3(2):211-217.
[3] GÜLER TEZEL G,ŞENER E,AYDIN Ç,et al.Prevalence of epidermal growth factor receptor mutations in patients with non-small cell lung gancer in Turkish population[J].Balkan Med J,2017,34(6):567-571.
[4] SUN E G,LEE K H,KO Y S,et al.KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3-ligase Nrdp1-mediated degradation[J].Mol Carcinog,2017,56(3):1068-1081.
[5] CHO Y T,CHEN K L,SHEEN Y S,et al.Purpuric drug eruptions caused by epidermal growth factor receptor inhibitors for non-small cell lung cancer:a clinicopathologic study of 32 cases[J].JAMA Dermatol,2017,153(9):906-910.
[6] MENEZES S V,SAHNI S,KOVACEVIC Z,et al.Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling[J].J Biol Chem,2017,292(31):12772-12782.
[7] LIU Y,SONG L,NI H,et al.ERBB4 acts as a suppressor in the development of hepatocellular carcinoma[J].Carcinogenesis,2017,38(4):465-473.
[8] SAHU A,PATRA P K,YADAV M K,et al.Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy[J].J Recept Signal Transduct Res,2017,37(5):470-480.
[9] MA X,LI L,TIAN T,et al.Study of lung cancer regulatory network that involves erbB4 and tumor marker gene[J].Saudi J Biol Sci,2017,24(3):649-657.
[10] SAGLAM O,XIONG Y,MARCHION D C,et al.ERBB4 expression in ovarian serous carcinoma resistant to platinum-based therapy[J].Cancer Control,2017,24(1):89-95.
[11] OHASHI Y,KUMAGAI K,MIYATA Y,et al.Overexpression of ErbB4 is an independent marker for lymph node metastasis in Japanese patients with oral squamous cell carcinoma[J].Oral Surg Oral Med Oral Pathol Oral Radiol,2016,122(3):313-321.
[12] 崔曼莉,张超,张明鑫,等.HIF-1α与ERBB4在食管鳞癌中的表达及意义[J].山西医科大学学报,2016,47(9):830-833.
[13] 谭永辉,吕品,聂盛丹,等.肝内胆管癌中ErbB4的表达及临床意义[J].中国普通外科杂志,2015,24(2):180-184.
[14] ZHANG M,ZHANG L,CUI M,et al.miR-302b inhibits cancer-related inflammation by targeting ERBB4,IRF2 and CXCR4 in esophageal cancer[J].Oncotarget,2017,8(30):49053-49063.
[15] SONG G,ZHANG H,CHEN C,et al.miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression[J].Oncotarget,2017,8(28):45725-45735.
[16] 叶文广,姚青林,张明鑫,等.miR-520a调控ErbB4的表达并抑制食管鳞癌细胞的增殖与侵袭[J].南方医科大学学报,2014,34(2):164-168.
[17] 彭思远,曾杰宏,谢博文,等.阻断ErbB4受体对人胆管细胞癌QBC939细胞系增殖与转移的影响[J].湖南师范大学学报(医学版),2017,14(2):23-26.
[18] 杨锁萍,丁为民,李凯,等.EGFR突变阴性非小细胞肺癌二、三线治疗的荟萃分析[J].东南大学学报(医学版),2015,34(6):859-867.
[19] 郑亮,刘爽,亓倩,等.干扰Mig-6基因表达对非小细胞肺癌EGFR信号通路的影响[J].东南大学学报(医学版),2017,36(3):416-421.
[20] BOJKO A,CIERNIAK A,ADAMCZYK A,et al.Modulatory effects of curcumin and tyrphostins (AG494 and AG1478) on growth regulation and viability of LN229 human brain cancer cells[J].Nutr Cancer,2015,67(7):1170-1182.
[21] 马聪玲,殷一萍,毛婷婷,等.EGFR抑制剂AG1478对宫颈癌HeLa细胞凋亡的影响[J].实用医学杂志,2017,33(2):202-205. |